Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
monoclonal antibody against O antigen O25b
- Development stage
- Preclinical
- Lead developer
- X4 Pharmaceuticals
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
BB100 (formerly ASN-4) is a humanized monoclonal antibody (IgG1) that specifically targets the O25b O-antigen of the lipopolysaccharide (LPS) of multidrug-resistant *Escherichia coli* sequence type 131 (ST131-O25b:H4) clonal lineage. Originally discovered by Arsanis under the ASN200 program and subsequently licensed to Bravos Biosciences (via its subsidiary BB100, LLC), BB100 exhibits multiple modes of action, including direct complement-mediated bactericidal activity, opsonophagocytic killing, and endotoxin neutralization by preventing LPS-induced activation of Toll-like receptor 4 (TLR4). It is being developed for the prevention and treatment of serious extraintestinal pathogenic *E. coli* (ExPEC) infections, particularly in high-risk or colonized patients.
- Other names
- 3E9-11A1124A-1124A 1124anti-O25b monoclonal antibodyanti-O-25b monoclonal antibodyanti-O 25b monoclonal antibodyα-ST131 mAbα-ST131:O25b mAb
02
Targets
Complement (Complement system)TLR4 (Toll-like receptor 4)O25b (Escherichia coli O25b antigen)
Beyond the preview
Go deeper on monoclonal antibody against O antigen O25b.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on monoclonal antibody against O antigen O25b.